Effectiveness of highly active antiretroviral therapy (HAART) among HIV-infected patients in Mexico

AIDS Research and Human Retroviruses

Volumn 26, Issue 4, 2010, Pages 373-378

  Crabtree Ramírez, Brenda ^a   Villasís Keever, Angelina ^a   Galindo Fraga, Arturo ^a   Del Río, Carlos ^b   Sierra Madero, Juan ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE; AGED; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROGRAM; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INFECTION RISK; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEXICO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT PLANNING; TUBERCULOSIS; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICALLY UNINSURED; MEXICO; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; RISK FACTORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 77951816263     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0077     Document Type: Article

References (19)

1. Pallela F, Loveless MO, Fuhrer J, Satten GA, and Aschman DJ: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338(13):853-860.
2. Mocroft A, Ledergerber B, Katlama C, et al.: Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362:22-29.
3. Galvao J: Access to antiretroviral drugs in Brazil. Lancet 2002;360:1862-1865.
4. Teixeira PR, Vitoria MA, and Barcarolo J: Antiretroviral treatment in resource-poor settings: The Brazilian experience. AIDS 2004;18(Suppl):S5-S7.
5. Marins JR, Jamal LF, Chen SY, et al.: Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003;17:1675-1682.
6. Koenig SP, Leandre F, and Farmer PE: Scaling-up HIV treatment programs in resource-limited settings: The rural Haiti experience. AIDS 2004;18(Suppl):S21-S25.
7. Laurent F, Arnaud J, Loretxu P, et al.: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet 2006;367:1335-1342.
8. Alcorn K: Mexico plans free AIDS treatment. AIDSMAP; 2003 http:==www.aidsmap.com=news.
9. Sepkowitz K: Two epidemics-AIDS at 25. New Engl J Med 2006;354:2411
10. Gutiérrez JP, López Zaragoza JL, Valencia Mendoza A, Pesqueira E, Ponce de León S, and Bertozzi SM: Haciendo frente a la epidemia de VIH=SIDA en México: Una respuesta organizada? Rev Invest Clín 2004;56:242.
11. ART-Cohort Collaboration: HIV treatment response and prognosis in Europe and North America in the first decade of highly antiretroviral therapy: A collaborative analysis. Lancet 2006;368:451.
12. Bautista A S, Mane A, and Bertozzi SM: Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment. AIDS 2006;20:101.
13. Chequer P, Cuchi P, Mazin R, et al.: Access to antiretroviral treatment in Latin American countries and the Caribbean. AIDS 2002;16(Suppl):50.
14. The Antiretroviral Therapy in Lower Income Countries (ARTLINC) Collaboration and Antiretroviral Cohort Collaboration (ART-CC) groups: Mortality of HIV-1 infected patients in first year of antiretroviral therapy: Comparison between lowincome and high-income countries. Lancet 2006;367:817.
15. Tuboi S, Shepherd B, Cesar C, et al.: Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients from 5 treatment centers in the Caribbean and Latin America. XVII International AIDS Conference, Mexico City. Abstract MOAB0203.
16. Ferradini L, Jeannin A, Pinoges L, et al.: Scaling up for highly active antiretroviral therapy in a rural district of Malawi: An effectiveness assessment. Lancet 2006;367:1335.
17. Sabin CA, Smith CJ, Youle M, et al.: Deaths in the era of HAART: Contribution of late presentation, treatment exposure, resistance and abnormal markers. AIDS 2006;20:67.
18. Lucas G, Chiasson RE, and Moore RD: Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81.
19. Hacker MA, Peterson ML, Enriquez M, et al.: Highly active antiretroviral therapy in Brazil: The challenge of universal access in a context of social inequality. Pan Am J Public Health 2004;16:78.